STI-571: an anticancer protein-tyrosine kinase inhibitor

Department of Biochemistry and Molecular Biology, Louisiana State University Health Sciences Center, 1100 Florida Avenue, New Orleans, LA 70119, USA.
Biochemical and Biophysical Research Communications (Impact Factor: 2.28). 11/2003; 309(4):709-17. DOI: 10.1016/j.bbrc.2003.08.055
Source: PubMed

ABSTRACT STI-571 (imatinib, Gleevec, Glivec, CGP 57148) is an inhibitor of the Abl group of protein-tyrosine kinases. One of these enzymes, the Bcr-Abl oncoprotein, results from the fusion of the BCR and ABL genes that result from the reciprocal chromosomal translocation that forms the Philadelphia chromosome. The Philadelphia chromosome occurs in 95% of people with chronic myeloid leukemia. ABL is the cellular homologue of the oncogene found in murine Abelson leukemia virus, and BCR refers to breakpoint cluster region. The Bcr-Abl oncoprotein exhibits elevated protein-tyrosine kinase activity, which is strongly implicated in the mechanism of development of chronic myeloid leukemia. STI-571 is effective in the treatment of the stable phase of chronic myeloid leukemia. The c-Abl protein kinase domain exists in an active and inactive conformation. STI-571 binds only to the inactive state of the enzyme as shown by X-ray crystallography. The drug binds to a portion of the ATP-binding site and extends from there into adjacent hydrophobic regions. STI-571 is a competitive inhibitor of Abl kinase with respect to ATP. Resistance to STI-571 is often the result of mutations in residues of the Bcr-Abl kinase that ordinarily bind to the drug. Inhibition of target protein kinases represents an emerging therapeutic strategy for the treatment of cancer.

  • [Show abstract] [Hide abstract]
    ABSTRACT: An efficient, waste-free protocol has been developed for the synthesis of amides directly from nonactivated carboxylic acids and amines without any tedious purification. Fatty acids were also converted into corresponding amides by reaction with nonactivated amines. The synthesized amides were cyclized to tetrahydroisoquinolines in good yields.
    Synthetic Communications 04/2015; 45(7). DOI:10.1080/00397911.2014.984853 · 0.98 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The emergence of multidrug-resistance strains of Mycobacterium tuberculosis has intensified efforts to discover novel drugs for tuberculosis treatment. Targeting the persistant state of Mycobacterium tuberculosis, in which Mycobacterium tuberculosis is resistant to conventional drug therapies, is of particular interest. PknB is most important protein kinases in causing tuberculosis disease. This protein has also some variation, two threonine residues in the activation loop, found in the mostly disordered in the crystal structure of this kinase, namely Thr171 and Thr173, were identified as the target for PknB autophosphorylation.It is a functional kinase i.e. autophosphorylation on serine-threonine residue and also able to phosphorylates the peptide substrates. GarA plays direct role in causing tuberculosis disease. The main aim of this project is to design a potent drug against 'catalytic/protein kinase domain' of trans-membrane signaling enzyme 'eukaryotic like-Serine-threonine protein kinase B' (PknB) from Mycobacterium tuberculosis by 'molecular docking approach'. In this, 50 drugs designed and screened against PknB as receptor based on the lowest energy with repeated conformation of ligands and, passed through ADME/TOPKAT toxicity prediction to sort out the toxic compounds. Then 10 drugs were selected which were not toxic and docked with the PknB receptor protein. Binding
    World Journal of Pharmaceutical Research 02/2014; 3(2). · 5.99 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Cancer cells often become resistant to chemotherapy through a phenomenon known as multidrug resistance (MDR). Several factors are responsible for the development of MDR, preeminent among them being the accelerated drug efflux mediated by overexpression of ATP binding cassette (ABC) transporters. Some small molecule tyrosine kinase inhibitors (TKIs) were recently reported to modulate the activity of ABC transporters. Therefore, the purpose of this study was to determine if motesanib, a multikinase inhibitor, could reverse ABCB1-mediated MDR. The results showed that motesanib significantly sensitized both ABCB1-transfected and drug-selected cell lines overexpressing this transporter to its substrate anticancer drugs. Motesanib significantly increased the accumulation of [3H]-paclitaxel in ABCB1 overexpressing cells by blocking the efflux function of ABCB1 transporter. In contrast, no significant change in the expression levels and localization pattern of ABCB1 was observed when ABCB1 overexpressing cells were exposed to 3μM motesanib for 72h. Moreover, motesanib stimulated the ATPase activity of ABCB1 in a concentration-dependent manner, indicating a direct interaction with the transporter. Consistent with these findings, the docking studies indicated favorable binding of motesanib within the transmembrane region of homology modeled human ABCB1. Here, we report for the first time, motesanib, at clinically achievable plasma concentrations, antagonizes MDR by inhibiting the efflux activity of the ABCB1 transporter. These findings may be useful for cancer combination therapy with TKIs in the clinic.
    Biochemical Pharmacology 06/2014; 90(4):367-378. DOI:10.1016/j.bcp.2014.06.006. · 4.65 Impact Factor

Preview (2 Sources)

Available from